Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track PMN with free AI briefings, catalyst countdowns, and dilution alerts.

PMN · ProMIS Neurosciences Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$53.5M Cash on Hand
14.1mo Cash Runway
Follow PMN by email Get an email when PMN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about PMN, unsubscribe in one click. Privacy

📣 What PMN Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
PMN310 Alzheimer Disease, Early Onset Phase 1 · NCT06750432 Active not recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

PMN holds $53.5M in cash and short-term investments (as of Jun 30, 2026) and burns about $11.4M/quarter from operations, an estimated runway of 14.1 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 38 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when PMN files for a raise →

👥 Who Owns PMN

Insiders 100% Institutions (32 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Jeremy M. Sclar
10% owner · +3.14M options
Insider 7,246,296 80.54% 2025-07-25
Slanix Paul Alex
Director · +11,000 options
Insider 6,058,738 67.34% 2025-10-22
Shaf QIC LLC
10% owner
Insider 5,184,760 57.63% 2025-07-29
Jeremy M. Sclar 2012 Irrevocable Family
10% owner · +3.14M options
Insider 3,710,459 41.24% 2025-07-25
Michael S Gordon
See Remarks section. · +1.58M options
Insider 2,435,029 27.07% 2025-07-25
Fan Yu 5%+ holder (13D) 1,644,397 18.28% 2026-02-03
JANUS HENDERSON GROUP PLC Institution (13G, 5%+) 1,292,757 14.37% 2026-03-31
ABG Management Ltd.
10% owner · +740,741 options
Insider 943,090 10.48% 2026-02-03
ABG V-SIV IX Ltd
10% owner
Includes shares also reported by ABG Management Ltd., counted once
Insider 943,090 10.48% 2026-02-03
Trails Edge Capital Partners, LP Institution (13G, 5%+) 933,477 10.38% 2026-02-03
Deep Track Capital, LP Institution (13G, 5%+) 902,561 10.03% 2026-01-30
Adage Capital Management, L.P. Institution (13G, 5%+) 703,550 7.82% 2026-09-30

Share count 8,996,862 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full PMN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PMN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.